AUTHORS
Liang Zhang, PhD, Ran Zhao, MSc2, Kazuharu Kamachi, MD, PhD3, Saurabh Kumar Kumar Gupta, Postdoctoral Fellow4, Hiroki Akiyama5, Yuki Nishida, MD, PhD6, Bing Z Carter, PhD7, Michael Andreeff, MD, PhD8, Jo Ishizawa, MD, PhD9
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 Institute of Science Tokyo, Tokyo, Japan
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Resistance to apoptosis remains a major therapeutic challenge in acute myeloid leukemia (AML). Ferroptosis, a distinct form of regulated cell death driven by iron-dependent lipid peroxidation, has emerged as an alternative therapeutic strategy capable of bypassing apoptosis resistance. We previously demonstrated that depletion of glutathione peroxidase 4 (GPX4), the primary defense against ferroptosis, profoundly suppresses leukemia (PMID: 38148395). However, despite its antileukemic activity, GPX4 depletion confers only modest survival benefit in AML xenograft models, suggesting that AML cells engage additional ferroptosis-resistance mechanisms that limit the therapeutic efficacy of GPX4 inhibition.
Despite the identification of several ferroptosis defense pathways, the molecular determinants governing ferroptosis susceptibility remain highly context dependent and are incompletely defined in AML. To systematically identify AML-specific regulators that modulate ferroptosis susceptibility and may improve ferroptosis-based therapies, we performed a genome-wide CRISPR/Cas9 knockout screen in MOLM13 cells under ferroptotic stress. Ferroptosis was induced using a doxycycline-inducible short hairpin RNA (shRNA) targeting GPX4, enabling selective identification of genetic determinants that promote ferroptosis resistance or sensitivity. The screen robustly identified multiple established ferroptosis-promoting genes, including ACSL4, DHCR7, and LPCAT3, as well as canonical ferroptosis suppressors, including SLC7A11 and GCH1, validating the robustness and reliability of the screening dataset. Among the highest-confidence candidate genes, we identified MAFG (ranked #9), a small musculoaponeurotic fibrosarcoma (sMAF) family basic leucine zipper transcription factor, as a previously unrecognized candidate regulator of ferroptosis resistance in AML. Analysis of publicly available AML datasets revealed that MAFG is significantly overexpressed in AML, and that elevated MAFG expression positively correlates with resistance to multiple structurally distinct ferroptosis inducers, including ML162, RSL3, ML210, and Erastin (Cancer Therapeutics Response Portal, z-score: 5.05, 4.54, 3.91, and 3.27, respectively), supporting a broad role for MAFG in ferroptosis defense. Furthermore, MAFG expression is positively associated with the expression of the canonical ferroptosis regulator SLC7A11 in primary AML patient samples (ρ=0.417, q=4.52 x 10-19 in Beat AML dataset; ρ=0.495, q=0.00144 in TARGET AML dataset), suggesting that MAFG participates in a clinically relevant antioxidant regulatory network.
To investigate the underlying mechanism, we integrated protein interaction network analysis with publicly available datasets, which revealed that MAFG transcriptionally activates antioxidant genes by forming a heterodimer with NRF2 (NFE2L2), a central hub in the SLC7A11-GPX4 regulatory network. Consistently, published ChIP-seq datasets demonstrated MAFG occupancy at the SLC7A11 promoter and the GPX4 enhancer in K562 cells. Functional validation using luciferase reporter assays confirmed that MAFG significantly increased the transcriptional activity of SLC7A11 promoter and the GPX4 enhancer by approximately 2.5-fold (p<0.0001). Moreover, ectopic MAFG expression markedly increased SLC7A11 mRNA expression (4.26-fold, p=0.0004) and modestly elevated GPX4 expression (1.33-fold, p=0.0525) by quantitative RT-PCR, consistent with the reporter assay results. Functionally, MAFG overexpression markedly increased ferroptosis resistance in MOLM13 (RSL3 IC50: 104nM vs. 60nM in parental cells). Conversely, CRISPR-engineered knockout of MAFG significantly enhanced ferroptotic cell death in AML cells treated with a low concentration of RSL3 (80nM for 20h), resulting in approximately 3-fold increased cell death (p<0.0001). Importantly, this phenotype was completely rescued by the ferroptosis inhibitor Ferrostatin-1, confirming that the observed cell death was ferroptosis dependent.
Conclusion: These findings identify MAFG as a previously unrecognized upstream transcriptional regulator of the SLC7A11-GPX4 antioxidant axis that suppresses ferroptosis and may function as a key mediator of compensatory ferroptosis resistance in AML, providing a mechanistic rationale for targeting MAFG to enhance the therapeutic efficacy of ferroptosis-based therapies.
DISCLOSURES
Liang Zhang, PhD: No relevant conflicts of interest to declare.